Full-Time

Cybersecurity Analyst

RDT Security Platforms

Roche

Roche

1-10 employees

Global pharmaceuticals and diagnostics company

No salary listed

Madrid, Spain

In Person

Category
IT & Security (1)
Required Skills
PowerShell
Bash
Microsoft Azure
Agile
Python
GitHub Actions
Git
ServiceNow
Computer Networking
Cybersecurity
AWS
Jenkins
Terraform
Ansible
DevOps
Google Cloud Platform

Get referred to Roche

See people who can refer or advise you

Requirements
  • The candidate must be self-motivated and capable of owning work end-to-end with minimal direction.
  • The candidate must independently lead the analysis of moderately complex cybersecurity incidents and technical problems, define the security problem scope, and drive root cause analysis for security breaches or vulnerabilities.
  • The candidate must identify security stakeholders across functional areas and manage relationships using deep business and technical understanding.
  • The candidate must provide responsive customer-focused service delivery and support.
  • The candidate must collaborate and communicate effectively across distributed, cross-functional teams.
  • The candidate must be detail-oriented and committed to quality, documentation, and operational excellence.
  • The candidate must have strong written and verbal English communication skills.
  • The candidate must have 3-7 years of hands-on technical experience in security engineering focused on network security and secure access technologies.
  • The candidate must have hands-on experience with web application firewalls, including designing and conducting proof-of-concept evaluations of new solutions.
  • The candidate must be proficient with Terraform or similar infrastructure-as-code tools and GitHub for version control and collaboration.
  • The candidate must have experience using ServiceNow for configuration management, configuration management database, change management, or incident management.
  • The candidate must have experience with automation, including scripts, workflows, or continuous integration and continuous delivery, to support security operations.
  • The candidate must have a strong understanding of network security concepts, including Zero Trust, virtual private networks, domain name system, firewalls, and web proxies.
  • The candidate must have scripting or programming skills in Python, PowerShell, Bash, or a similar language.
Responsibilities
  • Design, implement, and operate web application firewall-based web security and Zero Trust access solutions.
  • Lead design and proof-of-concept evaluations for new web application firewall and secure access solutions.
  • Manage web application firewall configuration, policy tuning, and day-to-day operations.
  • Support automation efforts to reduce manual work across security configurations.
  • Manage infrastructure-as-code using Terraform and maintain version-controlled configurations in GitHub.
  • Own configuration management processes in ServiceNow, ensuring accurate configuration management database records and change management compliance.
  • Ensure security solutions meet regulatory requirements and support audit and compliance activities.
  • Identify gaps in access controls and propose improvements.
  • Collaborate with network, identity, and cloud teams to deliver integrated secure access capabilities.
  • Mentor more junior team members and contribute to the development of security best practices.
Desired Qualifications
  • Prior experience in a regulated industry such as healthcare, finance, pharma, or government.
  • Familiarity with Agile and DevOps practices and experience with continuous integration and continuous delivery tooling such as GitHub Actions, Jenkins, or Ansible.
  • Experience with AWS, Azure, or Google Cloud Platform cloud security services.
  • Exposure to security information and event management, endpoint detection and response, or broader security operations tooling.
  • Relevant certifications such as PCNSE, Cloudflare Certified, CCNP Security, or equivalent.
  • Cloudflare experience with web application firewalls.

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Get referred to Roche

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • H1 2026 sales rose 6% CER, with core operating profit up 10%.
  • FDA cleared cobas BV/CV and PTEN assays in July 2026, expanding diagnostics revenue.
  • CHMP recommended Susvimo in July 2026, unlocking a differentiated EU eye-care launch.

What critics are saying

  • Genentech sued Biocon July 30, 2026 over Perjeta biosimilar, signaling franchise erosion.
  • Roche faces CHF0.6 billion 2026 loss-of-exclusivity pressure, crushing slower launches.
  • Kadcyla and Ocrevus expiration timelines threaten Roche’s oncology and immunology cash engine.

What makes Roche unique

  • Roche uniquely pairs blockbuster medicines with diagnostics, selling tests alongside therapies worldwide.
  • AXELIOS 1 and PathAI deepen Roche’s moat in sequencing and AI pathology.
  • Susvimo and cobas BV/CV show Roche turns specialty science into practical platform products.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company News

PR Newswire
Aug 6th, 2026
Roche expands cyclospora testing portfolio with three new assays for US public health labs

Roche has expanded its cyclospora testing portfolio with two new research-use-only molecular PCR tests to support U.S. public health response efforts. The LightMix Modular Cyclospora assay specifically detects cyclospora, whilst the LightMix OneTube Gastro Para 2 assay detects multiple parasites including Entamoeba histolytica, Giardia, and Cyclospora cayetanensis. Both tests work with LightCycler 480 and LightCycler PRO instruments. They complement an existing assay compatible with cobas 5800, 6800, and 8800 systems. The portfolio offers flexible testing options with one, three, or six targets. Roche acquired TIB MOLBIOL in December 2021 to expand its PCR-test capabilities for emerging infectious diseases. The company's testing infrastructure includes assays for hepatitis, HIV, respiratory illnesses, and vector-borne diseases.

PR Newswire
Jul 24th, 2026
Roche receives FDA clearance for cobas BV/CV assay for fast vaginitis diagnosis

Roche has received FDA 510(k) clearance for its cobas BV/CV assay, a molecular diagnostic test that detects bacterial vaginosis and Candida vaginitis from a single vaginal swab sample. The PCR-based test aims to improve diagnostic accuracy compared to traditional methods like microscopy and pH testing, which have misdiagnosis rates approaching 50%. Bacterial vaginosis affects approximately 27% of women of reproductive age in North America, whilst up to 75% of women experience Candida vaginitis at least once in their lifetime. The assay uses real-time PCR technology to identify specific bacteria and yeast responsible for these conditions. The test expands Roche's sexual health testing menu on its cobas 6800/8800 systems, enabling comprehensive testing for multiple conditions from a single sample. Commercial launch is expected later this year.

Yahoo Finance
Jul 24th, 2026
Roche's Susvimo receives EU approval recommendation as first continuous nAMD treatment requiring just two refills per year

Roche's Susvimo has received a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use for treating neovascular age-related macular degeneration (nAMD). Susvimo is the first continuous delivery treatment that offers an alternative to standard eye injections for nAMD, requiring only two refills per year through the Contivue refillable implant. The recommendation is based on data from the LADDER, Archway and Portal studies, which showed Susvimo maintained vision equivalent to monthly intravitreal ranibizumab injections, with data supporting vision maintenance up to seven years. Approximately 95% of patients treated with Susvimo required no supplemental treatment. nAMD is a leading cause of blindness in people over 60 and affects 1.7 million in the EU. A final decision is expected from the European Commission soon.

Yahoo Finance
Jul 23rd, 2026
Roche sales grow 6% at constant exchange rates in H1 2026, led by Xolair and Hemlibra

Roche reported 6% sales growth at constant exchange rates in the first half of 2026, though this translated to a 2% decline in Swiss francs due to currency appreciation. The Swiss pharmaceutical and diagnostics company's performance was driven by strong demand for its innovative medicines and diagnostic products. The Pharmaceuticals Division grew 6% at constant exchange rates, led by Xolair, Hemlibra, Ocrevus, Phesgo, and Vabysmo. The Diagnostics Division increased 3% at constant exchange rates, driven by immunodiagnostic and clinical chemistry products. Core operating profit rose 10% at constant exchange rates. Core earnings per share grew 9% at constant exchange rates but fell 2% in Swiss francs. Key developments included multiple US priority reviews for drug candidates and positive phase III trial data. Roche also launched its Axelios 1 sequencing platform and announced an agreement to acquire PathAI. The company confirmed its 2026 outlook, expecting mid-single-digit sales growth at constant exchange rates.

Yahoo Finance
Jul 23rd, 2026
Roche appoints Dan Malarek to lead North America diagnostics business

Roche has appointed Dan Malarek as President and CEO of Roche Diagnostics North America. The leadership change affects a key operating segment within the Swiss healthcare company's business. Malarek previously led Foundation Medicine, a Roche affiliate focused on precision medicine and genomic insights. His background ties directly into themes shaping modern diagnostics use in healthcare. The diagnostics arm is central to how Roche supports hospitals, laboratories, and clinicians with testing platforms and data-driven tools. Areas such as test menu development, data integration with pharmaceuticals, and health system partnerships are potential focus points under the new leadership. Roche shares currently trade at CHF332.4, approximately 8% below the CHF359.2 analyst consensus target.